{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:59:15Z","timestamp":1790096355014,"version":"4.0.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The introduction of Direct-Acting Antivirals (DAAs) transformed Hepatitis C (HCV) treatment, despite this uptake of DAAs remains lower than required to meet the WHO Sustainable Development Goal (3.3). Treatment with interferon was suggested to be able to deliver important outcomes for people who use drugs in addition to a viral cure, such as social redemption, and shift from a stigmatised identity. There is a lack of understanding if DAAs can deliver these transformative outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This recurrent cross-sectional study combines qualitative semi-structured interviews and demographic data of 15 participants receiving DAAs in Tayside, Scotland. A thematic analysis explored the non-clinical outcomes of DAA treatment viewed through the lens of the Social Identity Model of Recovery (SIMOR) to build understanding of the influence DAAs have in a recovery journey from drug use.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Three key themes emerged: identity, relationships and social networks; building recovery capital; and reflecting on re-infection and the shift to DAAs. Concern about the transmission of HCV resulted in self-imposed isolation which weakened support structures. Cure provides a mechanism to strengthen family bonds, however social networks in the wider community remain limited. Participants gained opportunities to undertake activities that build health and wellbeing providing a shift in identity, future plans and aspirations. Social isolation remained for some, revealing unmet need in post-cure support.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>DAAs may support recovery journeys through the SIMOR, individuals reduced the number of active users within their social network and reconnected with family members, building recovery capital. Individuals, however, remained socially isolated in the context of the wider community. HCV services should support links to community resources to deliver the social inclusion people desire.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12954-024-01142-3","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T01:22:21Z","timestamp":1736990541000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Future destinations: how people cured of hepatitis C using direct acting antiviral drugs progress in a new HCV-free world. A thematic analysis"],"prefix":"10.1186","volume":"22","author":[{"given":"Sarah R.","family":"Donaldson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Radley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"key":"1142_CR1","unstructured":"Hickman M, Martin NK, Giraudon I, Wiessing L, Hedrich D, Kalamara E, Griffiths P, Simon R. Hepatitis C among drug users in Europe: epidemiology, treatment and prevention. Publication Office of the European Union; 2016."},{"key":"1142_CR2","unstructured":"World Health Organization. Global hepatitis report 2017. World Health Organization; 2017."},{"key":"1142_CR3","unstructured":"World Health Organization. Combating hepatitis B and C to reach elimination by 2030: advocacy brief. World Health Organization; 2016."},{"issue":"4","key":"1142_CR4","first-page":"217","volume":"27","author":"AI Newman","year":"2013","unstructured":"Newman AI, Beckstead S, Beking D, Finch S, Knorr T, Lynch C, MacKenzie M, Mayer D, Melles B, Shore R. Treatment of chronic hepatitis C infection among current and former injection drug users within a multidisciplinary treatment model at a community health centre. Can J Gastroenterol Hepatol. 2013;27(4):217\u201323.","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"7","key":"1142_CR5","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1111\/1467-9566.12018","volume":"35","author":"T Rhodes","year":"2013","unstructured":"Rhodes T, Harris M, Martin A. Negotiating access to medical treatment and the making of patient citizenship: the case of hepatitis C treatment. Sociol Health Illn. 2013;35(7):1023\u201344.","journal-title":"Sociol Health Illn"},{"key":"1142_CR6","doi-asserted-by":"crossref","unstructured":"Clark JA, Gifford AL. Resolute efforts to cure hepatitis C: Understanding patients\u2019 reasons for completing antiviral treatment. Health: 2015; 19(5):473\u2009\u2013\u200989.","DOI":"10.1177\/1363459314555237"},{"issue":"2","key":"1142_CR7","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.drugpo.2013.11.004","volume":"25","author":"L Jones","year":"2014","unstructured":"Jones L, Atkinson A, Bates G, McCoy E, Porcellato L, Beynon C, McVeigh J, Bellis MA. Views and experiences of hepatitis C testing and diagnosis among people who inject drugs: systematic review of qualitative research. Int J Drug Policy. 2014;25(2):204\u201311.","journal-title":"Int J Drug Policy"},{"issue":"3","key":"1142_CR8","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/add.12392","volume":"109","author":"J Rance","year":"2014","unstructured":"Rance J, Treloar C, ETHOS Study Group. Not just methadone T racy\u2019: transformations in service-user identity following the introduction of hepatitis C treatment into Australian opiate substitution settings. Addiction. 2014;109(3):452\u20139.","journal-title":"Addiction"},{"key":"1142_CR9","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.drugalcdep.2015.06.007","volume":"153","author":"AW Batchelder","year":"2015","unstructured":"Batchelder AW, Peyser D, Nahvi S, Arnsten JH, Litwin AH. Hepatitis C treatment turned me around: psychological and behavioral transformation related to hepatitis C treatment. Drug Alcohol Depend. 2015;153:66\u201371.","journal-title":"Drug Alcohol Depend"},{"key":"1142_CR10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.drugpo.2017.05.033","volume":"47","author":"AA Artenie","year":"2017","unstructured":"Artenie AA, Zang G, Daniel M, Fortier E, Jutras-Aswad D, Puzhko S, Bruneau J. Short-term injection drug use changes following hepatitis C virus (HCV) assessment and treatment among persons who inject drugs with acute HCV infection. Int J Drug Policy. 2017;47:239\u201343.","journal-title":"Int J Drug Policy"},{"key":"1142_CR11","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.drugpo.2017.03.015","volume":"47","author":"M Harris","year":"2017","unstructured":"Harris M. Managing expense and expectation in a treatment revolution: problematizing prioritisation through an exploration of hepatitis C treatment \u2018benefit\u2019. Int J Drug Policy. 2017;47:161\u20138.","journal-title":"Int J Drug Policy"},{"key":"1142_CR12","unstructured":"World Health Organization, Hepatitis C, Fact Sheet. 2024. https:\/\/who.int\/news-room\/fact-sheets\/detail\/hepatitis-c"},{"key":"1142_CR13","unstructured":"World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Geneva. World Health Organization, Licence CC BY-NC-SA 3.0 IGO; 2018."},{"key":"1142_CR14","doi-asserted-by":"publisher","first-page":"102596","DOI":"10.1016\/j.drugpo.2019.11.004","volume":"75","author":"M Stoov\u00e9","year":"2020","unstructured":"Stoov\u00e9 M, Wallace J, Higgs P, Pedrana A, Goutzamanis S, Latham N, Scott N, Treloar C, Crawford S, Doyle J, Hellard M. Treading lightly: finding the best way to use public health surveillance of hepatitis C diagnoses to increase access to cure. Int J Drug Policy. 2020;75:102596.","journal-title":"Int J Drug Policy"},{"issue":"3","key":"1142_CR15","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/liv.14324","volume":"40","author":"H Razavi","year":"2020","unstructured":"Razavi H, Sanchez Gonzalez Y, Yuen C, Cornberg M. Global timing of hepatitis C virus elimination in high-income countries. Liver Int. 2020;40(3):522\u20139.","journal-title":"Liver Int"},{"issue":"2","key":"1142_CR16","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41591-019-0706-x","volume":"26","author":"GJ Dore","year":"2020","unstructured":"Dore GJ, Martinello M, Alavi M, Grebely J. Global elimination of hepatitis C virus by 2030: why not? Nat Med. 2020;26(2):157\u201360.","journal-title":"Nat Med"},{"issue":"4","key":"1142_CR17","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/S2468-1253(23)00335-7","volume":"9","author":"AD Marshall","year":"2024","unstructured":"Marshall AD, Willing AR, Kairouz A, Cunningham EB, Wheeler A, O\u2019Brien N, Perera V, Ward JW, Hiebert L, Degenhardt L, Hajarizadeh B. Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions. Lancet Gastroenterol Hepatol. 2024;9(4):366\u201382.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1142_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.drugpo.2019.06.002","volume":"72","author":"J Bryant","year":"2019","unstructured":"Bryant J, Rance J, Hull P, Mao L, Treloar C. Making sense of \u2018side effects\u2019: counterpublic health in the era of direct-acting antivirals. Int J Drug Policy. 2019;72:77\u201383.","journal-title":"Int J Drug Policy"},{"key":"1142_CR19","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.drugpo.2018.07.015","volume":"60","author":"M Harris","year":"2018","unstructured":"Harris M, Rhodes T. Caring and curing: considering the effects of hepatitis C pharmaceuticalisation in relation to non-clinical treatment outcomes. Int J Drug Policy. 2018;60:24\u201332.","journal-title":"Int J Drug Policy"},{"key":"1142_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12954-018-0248-4","volume":"15","author":"A Madden","year":"2018","unstructured":"Madden A, Hopwood M, Neale J, Treloar C. Beyond cure: patient reported outcomes of hepatitis C treatment among people who inject drugs in Australia. Harm Reduct J. 2018;15:1\u20138.","journal-title":"Harm Reduct J"},{"key":"1142_CR21","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.drugpo.2019.03.015","volume":"72","author":"BE Williams","year":"2019","unstructured":"Williams BE, Nelons D, Seaman A, Witkowska M, Ronan W, Wheelock H, Zaman A, Garcia J. Life projects: the transformative potential of direct-acting antiviral treatment for hepatitis C among people who inject drugs. Int J Drug Policy. 2019;72:138\u201345.","journal-title":"Int J Drug Policy"},{"issue":"3","key":"1142_CR22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1080\/16066359.2018.1515352","volume":"27","author":"RD Ashford","year":"2019","unstructured":"Ashford RD, Brown A, Brown T, Callis J, Cleveland HH, Eisenhart E, Groover H, Hayes N, Johnston T, Kimball T, Manteuffel B. Defining and operationalizing the phenomena of recovery: a working definition from the recovery science research collaborative. Addict Res Theory. 2019;27(3):179\u201388.","journal-title":"Addict Res Theory"},{"issue":"3","key":"1142_CR23","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jsat.2007.06.001","volume":"33","author":"The Betty Ford Institute Panel","year":"2007","unstructured":"The Betty Ford Institute Panel. What is recovery? A working definition from the Betty Ford Institute. J Subst Abuse Treat. 2007;33(3):221\u20138.","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"1142_CR24","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jsat.2007.04.015","volume":"33","author":"WL White","year":"2007","unstructured":"White WL. Addiction recovery: its definition and conceptual boundaries. J Subst Abuse Treat. 2007;33(3):229\u201341.","journal-title":"J Subst Abuse Treat"},{"key":"1142_CR25","unstructured":"Best D, Laudet A. The potential of recovery capital. Volume 5. London: RSA; 2010 Jul."},{"key":"1142_CR26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.drugalcdep.2017.09.002","volume":"181","author":"I Cano","year":"2017","unstructured":"Cano I, Best D, Edwards M, Lehman J. Recovery capital pathways: modelling the components of recovery wellbeing. Drug Alcohol Depend. 2017;181:11\u20139.","journal-title":"Drug Alcohol Depend"},{"issue":"12\u201313","key":"1142_CR27","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1080\/10826080802289762","volume":"43","author":"W Cloud","year":"2008","unstructured":"Cloud W, Granfield R. Conceptualizing recovery capital: expansion of a theoretical construct. Subst Use Misuse. 2008;43(12\u201313):1971\u201386.","journal-title":"Subst Use Misuse"},{"issue":"2","key":"1142_CR28","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3109\/16066359.2015.1075980","volume":"24","author":"D Best","year":"2016","unstructured":"Best D, Beckwith M, Haslam C, Alexander Haslam S, Jetten J, Mawson E, Lubman DI. Overcoming alcohol and other drug addiction as a process of social identity transition: the social identity model of recovery (SIMOR). Addict Res Theory. 2016;24(2):111\u201323.","journal-title":"Addict Res Theory"},{"issue":"1","key":"1142_CR29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/jasp.12420","volume":"47","author":"R Bathish","year":"2017","unstructured":"Bathish R, Best D, Savic M, Beckwith M, Mackenzie J, Lubman DI. Is it me or should my friends take the credit? The role of social networks and social identity in recovery from addiction. J Appl Soc Psychol. 2017;47(1):35\u201346.","journal-title":"J Appl Soc Psychol"},{"issue":"2","key":"1142_CR30","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/bjso.12081","volume":"54","author":"GA Dingle","year":"2015","unstructured":"Dingle GA, Stark C, Cruwys T, Best D. Breaking good: breaking ties with social groups may be good for recovery from substance misuse. Br J Soc Psychol. 2015;54(2):236\u201354.","journal-title":"Br J Soc Psychol"},{"key":"1142_CR31","first-page":"117822181987657","volume":"13","author":"B Collinson","year":"2019","unstructured":"Collinson B, Best D. Promoting recovery from substance misuse through engagement with community assets: asset based community engagement. Subst Abuse: Res Treat. 2019;13:1178221819876575.","journal-title":"Subst Abuse: Res Treat"},{"key":"1142_CR32","doi-asserted-by":"crossref","unstructured":"Jetten J, Haslam C, Alexander SH. The social cure: identity, health and well-being. Psychology; 2012 Jan. p. 25.","DOI":"10.4324\/9780203813195"},{"key":"1142_CR33","doi-asserted-by":"crossref","unstructured":"Donaldson SR, Radley A, Dillon JF. Future destinations and social inclusion scoping review: how people cured of hepatitis C (HCV) using direct-acting antiviral drugs progress in a new HCV-free world. Substance Abuse Treatment, Prevention, and Policy. 2022;17(1):45.","DOI":"10.1186\/s13011-022-00475-1"},{"issue":"3","key":"1142_CR34","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/add.16031","volume":"118","author":"SR Donaldson","year":"2023","unstructured":"Donaldson SR, Radley A, Dillon JF. Transformation of identity in substance use as a pathway to recovery and the potential of treatment for hepatitis C: a systematic review. Addiction. 2023;118(3):425\u201337.","journal-title":"Addiction"},{"issue":"4","key":"1142_CR35","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1136\/medhum-2023-012653","volume":"49","author":"D Kagan","year":"2023","unstructured":"Kagan D, Seear K, Lenton E, Farrugia A, Mulcahy S. I\u2019m not hep C free\u2019: afterlives of hepatitis C in the era of cure. Med Humanit. 2023;49(4):678\u201387.","journal-title":"Med Humanit"},{"key":"1142_CR36","doi-asserted-by":"publisher","first-page":"103042","DOI":"10.1016\/j.drugpo.2020.103042","volume":"94","author":"K Seear","year":"2021","unstructured":"Seear K, Fraser S, Farrugia A. Beyond a \u2018post-cure\u2019 world: sketches for a new futurology of hepatitis C. Int J Drug Policy. 2021;94:103042.","journal-title":"Int J Drug Policy"},{"key":"1142_CR37","doi-asserted-by":"crossref","unstructured":"Fraser S, Seear K. Making disease, making citizens: the politics of hepatitis C. Routledge; 2016 May. p. 13.","DOI":"10.4324\/9781315593296"},{"key":"1142_CR38","doi-asserted-by":"publisher","first-page":"103610","DOI":"10.1016\/j.drugpo.2022.103610","volume":"102","author":"AD Marshall","year":"2022","unstructured":"Marshall AD, Rance J, Grebely J, Treloar C. Not just one box that you tick off\u2019\u2013Deconstructing the hepatitis C care cascade in the interferon-free direct acting antiviral era from the client perspective. Int J Drug Policy. 2022;102:103610.","journal-title":"Int J Drug Policy"},{"issue":"10","key":"1142_CR39","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.drugpo.2015.07.007","volume":"26","author":"J Grebely","year":"2015","unstructured":"Grebely J, Bruggmann P, Treloar C, Byrne J, Dore GJ. Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs. Int J Drug Policy. 2015;26(10):893\u20138.","journal-title":"Int J Drug Policy"},{"issue":"5","key":"1142_CR40","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/apt.16728","volume":"55","author":"CJ Byrne","year":"2022","unstructured":"Byrne CJ, Beer L, Inglis SK, Robinson E, Radley A, Goldberg DJ, Hickman M, Hutchinson S, Dillon JF. Real-world outcomes of rapid regional hepatitis C virus treatment scale\u2010up among people who inject drugs in Tayside, Scotland. Aliment Pharmacol Ther. 2022;55(5):568\u201379.","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"1142_CR41","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S2468-1253(20)30120-5","volume":"5","author":"A Radley","year":"2020","unstructured":"Radley A, De Bruin M, Inglis SK, Donnan PT, Hapca A, Barclay ST, Fraser A, Dillon JF. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial. Lancet Gastroenterol Hepatol. 2020;5(9):809\u201318.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"1142_CR42","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12889-022-14911-1","volume":"23","author":"E Robinson","year":"2023","unstructured":"Robinson E, Byrne CJ, Carberry J, Radley A, Beer LJ, Inglis SK, Tait J, Macpherson I, Goldberg D, Hutchinson SJ, Hickman M. Laying the foundations for hepatitis C elimination: evaluating the development and contribution of community care pathways to diagnostic efforts. BMC Public Health. 2023;23(1):54.","journal-title":"BMC Public Health"},{"key":"1142_CR43","unstructured":"University of Dundee. Elimination of Hepatitis C in Tayside [press release]. 28\/07\/2020. https:\/\/www.dundee.ac.uk\/stories\/nhs-tayside-first-region-world-elimination-hepatitis-c"},{"key":"1142_CR44","unstructured":"BBC News. NHS Tayside claims it has. effectively eliminated hepatitis C. 2020. https:\/\/www.bbc.co.uk\/news\/uk-scotland-tayside-central-53558315"},{"key":"1142_CR45","unstructured":"World Health Organization. The ASSIST project- Alcohol, Smoking and Substance Involvement Screening Tool 2010. https:\/\/www.who.int\/publications\/i\/item\/978924159938-2"},{"key":"1142_CR46","unstructured":"The University of Warwick. Collect, score, analyse and interpret WEMWBS https:\/\/warwick.ac.uk\/fac\/sci\/med\/research\/platform\/wemwbs\/using\/howto\/"},{"issue":"1","key":"1142_CR47","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1108\/TC-04-2013-0007","volume":"35","author":"D Best","year":"2014","unstructured":"Best D, Lubman I, Savic D, Wilson M, Dingle A, Alexander Haslam G, Haslam S, Jetten C. Social and transitional identity: exploring social networks and their significance in a therapeutic community setting. Therapeutic Communities: Int J Therapeutic Communities. 2014;35(1):10\u201320.","journal-title":"Therapeutic Communities: Int J Therapeutic Communities"},{"issue":"2","key":"1142_CR48","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Res Psychol. 2006;3(2):77\u2013101.","journal-title":"Qualitative Res Psychol"},{"key":"1142_CR49","doi-asserted-by":"crossref","unstructured":"Ritchie J, Spencer L. Qualitative data analysis for applied policy research. Analyzing qualitative data 2002 sep 9 (pp. 187\u2013208). Routledge.","DOI":"10.4324\/9780203413081-14"},{"issue":"9","key":"1142_CR50","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1097\/ACM.0000000000000388","volume":"89","author":"BC O\u2019Brien","year":"2014","unstructured":"O\u2019Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative research: a synthesis of recommendations. Acad Med. 2014;89(9):1245\u201351.","journal-title":"Acad Med"},{"key":"1142_CR51","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1007\/s11606-008-0790-y","volume":"23","author":"EJ Groessl","year":"2008","unstructured":"Groessl EJ, Weingart KR, Kaplan RM, Clark JA, Gifford AL, Ho SB. Living with hepatitis C: qualitative interviews with hepatitis C-infected veterans. J Gen Intern Med. 2008;23:1959\u201365.","journal-title":"J Gen Intern Med"},{"issue":"6","key":"1142_CR52","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1177\/135910530100600606","volume":"6","author":"EA Dunne","year":"2001","unstructured":"Dunne EA, Quayle E. The impact of iatrogenically acquired hepatitis C infection on the well-being and relationships of a group of Irish women. J Health Psychol. 2001;6(6):679\u201392.","journal-title":"J Health Psychol"},{"issue":"5","key":"1142_CR53","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1080\/16066359.2017.1297990","volume":"25","author":"EA Hennessy","year":"2017","unstructured":"Hennessy EA. Recovery capital: a systematic review of the literature. Addict Res Theory. 2017;25(5):349\u201360.","journal-title":"Addict Res Theory"},{"key":"1142_CR54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.35580\/jan.v1i2.38452","volume":"1","author":"DM Evon","year":"2022","unstructured":"Evon DM, Kim HP, Edwards A, Carda-Auten J, Reeve BB, Golin CE, Fried MW. If i get cured, my whole quality of life will change: patients\u2019 anticipated and actualized benefits following cure from chronic hepatitis C. Digestive diseases and sciences. Jan. 2022;1:1\u201321.","journal-title":"Jan"},{"key":"1142_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41124-018-0036-5","volume":"3","author":"JA Richmond","year":"2018","unstructured":"Richmond JA, Ellard J, Wallace J, Thorpe R, Higgs P, Hellard M, Thompson A. Achieving a hepatitis C cure: a qualitative exploration of the experiences and meanings of achieving a hepatitis C cure using the direct acting antivirals in Australia. Hepatol Med Policy. 2018;3:1\u20139.","journal-title":"Hepatol Med Policy"},{"issue":"2","key":"1142_CR56","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.drugpo.2003.10.009","volume":"15","author":"M Davis","year":"2004","unstructured":"Davis M, Rhodes T. Beyond prevention? Injecting drug user narratives about hepatitis C. Int J Drug Policy. 2004;15(2):123\u201331.","journal-title":"Int J Drug Policy"},{"issue":"10","key":"1142_CR57","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1111\/j.1360-0443.2008.02306.x","volume":"103","author":"T Rhodes","year":"2008","unstructured":"Rhodes T, Treloar C. The social production of hepatitis C risk among injecting drug users: a qualitative synthesis. Addiction. 2008;103(10):1593\u2013603.","journal-title":"Addiction"},{"issue":"7","key":"1142_CR58","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1111\/j.1467-9566.2009.01172.x","volume":"31","author":"M Harris","year":"2009","unstructured":"Harris M. Troubling biographical disruption: narratives of unconcern about hepatitis C diagnosis. Sociol Health Illn. 2009;31(7):1028\u201342.","journal-title":"Sociol Health Illn"},{"issue":"9","key":"1142_CR59","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1177\/1049732309341656","volume":"19","author":"C Treloar","year":"2009","unstructured":"Treloar C, Rhodes T. The lived experience of hepatitis C and its treatment among injecting drug users: qualitative synthesis. Qual Health Res. 2009;19(9):1321\u201334.","journal-title":"Qual Health Res"},{"issue":"1","key":"1142_CR60","first-page":"3268650","volume":"2017","author":"LE Dowsett","year":"2017","unstructured":"Dowsett LE, Coward S, Lorenzetti DL, MacKean G, Clement F. Living with hepatitis C virus: a systematic review and narrative synthesis of qualitative literature. Can J Gastroenterol Hepatol. 2017;2017(1):3268650.","journal-title":"Can J Gastroenterol Hepatol"},{"key":"1142_CR61","doi-asserted-by":"publisher","first-page":"116416","DOI":"10.1016\/j.socscimed.2023.116416","volume":"340","author":"A Farrugia","year":"2024","unstructured":"Farrugia A, Lenton E, Seear K, Kagan D, Fraser S, Mulcahy S, Edwards M, Jeffcote D. We\u2019ve got a present for you\u2019: Hepatitis C elimination, compromised healthcare subjects and treatment as a gift. Soc Sci Med. 2024;340:116416.","journal-title":"Soc Sci Med"},{"issue":"7175","key":"1142_CR62","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/bmj.318.7175.48","volume":"318","author":"T Greenhalgh","year":"1999","unstructured":"Greenhalgh T, Hurwitz B. Why study narrative? BMJ. 1999;318(7175):48\u201350.","journal-title":"BMJ"},{"issue":"9","key":"1142_CR63","doi-asserted-by":"publisher","first-page":"637","DOI":"10.7326\/M16-2575","volume":"166","author":"O Falade-Nwulia","year":"2017","unstructured":"Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med. 2017;166(9):637\u201348.","journal-title":"Ann Intern Med"},{"issue":"5","key":"1142_CR64","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","volume":"73","author":"JM Pawlotsky","year":"2020","unstructured":"Pawlotsky JM, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, Marra F, Puoti M, Wedemeyer H. European Association for the study of the liver. EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol. 2020;73(5):1170\u2013218.","journal-title":"J Hepatol"},{"key":"1142_CR65","unstructured":"UK Government. Social prescribing: applying All Our Health, Office for Health Improvement and Disparities. 2022. https:\/\/www.gov.uk\/government\/publications\/social-prescribing-applying-all-our-health\/social-prescribing-applying-all-our-health"},{"issue":"3","key":"1142_CR66","doi-asserted-by":"publisher","first-page":"101596","DOI":"10.1016\/j.clinre.2020.101596","volume":"45","author":"F Roudot-Thoraval","year":"2021","unstructured":"Roudot-Thoraval F. Epidemiology of hepatitis C virus infection. Clin Res Hepatol Gastroenterol. 2021;45(3):101596.","journal-title":"Clin Res Hepatol Gastroenterol"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01142-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-024-01142-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01142-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T13:18:54Z","timestamp":1737033534000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-024-01142-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1142"],"URL":"https:\/\/doi.org\/10.1186\/s12954-024-01142-3","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,16]]},"assertion":[{"value":"26 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for the study was given by East of Scotland Research Ethics Service (REC ref 19\/ES\/0129), R&D approval and Caldicott approval was given by NHS Tayside.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SRD declares receipt of research grants from Gilead and Camurus. AR declares receipt of research grants from Abbvie, BMS, Pfizer, Gilead and Camurus. Lecture fees and honorariums from Abbvie and Gilead. JFD declares receipt of research grants, Lecture fees and honorariums from Abbvie, BMS, Gilead, MSD, and Roche.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}